Wednesday, April 04, 2012

Pharmaceutical Field - Pfizer may split branded and generic drug businesses


At a meeting with Goldman Sachs analysts, CEO Ian Read (pictured) indicated that he was willing to consider further divestment of non-core assets. According to analyst Jami Rubin, “a potential full-scale breakup” of Pfizer is on the cards.

Posted via email from Jack's posterous

No comments: